Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD.

Franck Rahaghi, Laurel Omert, Virginia Clark, Robert A Sandhaus

Journal: Journal of critical care 2020;54():212-219

PMID: 31614323

Abstract

Alpha-1 Antitrypsin Deficiency (AATD) is a progressive pulmonary disease under-recognized or misdiagnosed by clinicians. Patients with AATD can develop a variety of organ-specific complications and as a result, often require hospitalization and treatment within critical care and ICU settings. Due to the complexity of AATD there are minimal guidelines in place to address the specific and highly variable needs of these patients in the critical care setting. This review presents clinical considerations with respect to the management of patients with AATD and provides treatment recommendations for these patients in the critical care setting. In addition, we have outlined certain aspects of the care of this patient population that may be of interest to critical care practitioners. With greater disease awareness and earlier diagnosis the onset of symptoms can be delayed, which will ultimately reduce the frequency of deleterious health consequences.

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Address: Pulmonary and Critical Care Division, Cleveland Clinic Florida, Weston, Florida, United States. Electronic address: [email protected].; CSL Behring, King of Prussia, PA, United States. Electronic address: [email protected].; Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida, United States. Electronic address: [email protected].; Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, United States. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.